Serum Leptin Levels in Treatment-Naive Patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis

被引:21
|
作者
Evangelopoulos, Maria Eleftheria [1 ]
Koutsis, Georgios [1 ]
Markianos, Manolis [1 ]
机构
[1] Univ Athens, Eginit Hosp, Sch Med, Dept Neurol, 74 Vassilisis Sophias Ave, Athens 11528, Greece
关键词
D O I
10.1155/2014/486282
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several studies have investigated leptin levels in patients with multiple sclerosis (MS) with somewhat conflicting results. They have all focused on patients with established relapsing-remitting (RR) MS but have not specifically looked at patients with clinically isolated syndrome (CIS) suggestive of MS, in the early stages of disease. In this study, serum leptin levels were measured in 89 treatment-naive patients with CIS (53 patients) or RRMS (36 patients) and 73 controls searching for differences between the groups and for associations with several disease parameters. The expected significant sexual dimorphism in leptin levels (higher levels in females) was observed in both MS patients and controls. Increased leptin levels were found in female patients with RRMS compared to female controls (P = .003) and female CIS patients (P = .001). Female CIS patients had comparable levels to controls. Leptin levels correlated positively to disease duration, but not to EDSS, in female patients with RRMS. The results of the present study do not indicate involvement of leptin in the early stages of MS. Normal leptin levels in patients with CIS suggest that leptin does not have a pathogenic role. The ratio leptin/BMI increases during disease course in female MS patients in a time-dependent and disability-independent manner.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Clinical predictors of disability in treatment-naive relapsing-remitting multiple sclerosis patients
    Ivaniuk, A.
    Solodovnikova, I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 921 - 921
  • [2] Cholesterol levels in plasma and cerebrospinal fluid in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis
    Evangelopoulos, Maria-Eleftheria
    Koutsis, Georgios
    Boufidou, Fotini
    Markianos, Manolis
    NEUROBIOLOGY OF DISEASE, 2022, 174
  • [3] Serum and Cerebrospinal Fluid Prolactin levels in Male and Female Patients with Clinically-Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
    Markianos, M.
    Koutsis, G.
    Evangelopoulos, M. E.
    Mandellos, D.
    Sfagos, C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2010, 22 (06) : 503 - 508
  • [4] Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients
    Fox, Edward J.
    Wynn, Daniel
    Coles, Alasdair J.
    Palmer, Jeffrey
    Margolin, David H.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 363 : 188 - 194
  • [5] Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome
    Jernas, Lukasz
    Wencel, Jacek
    Wiak, Andrzej
    Bieniek, Marek
    Bartosik-Psujek, Halina
    PLOS ONE, 2016, 11 (10):
  • [6] Cerebrospinal fluid proteome profile in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis
    Tumani, Hayrettin
    Rau, Daniela
    Palm, Christian
    Brettschneider, Johannes
    Suessmuth, Sigurd
    Lehmensiek, Vera
    MULTIPLE SCLEROSIS, 2008, 14 : S290 - S290
  • [7] High-Efficacy Therapies for Treatment-Naive Individuals with Relapsing-Remitting Multiple Sclerosis
    Freeman, Leorah
    Longbrake, Erin E.
    Coyle, Patricia K.
    Hendin, Barry
    Vollmer, Timothy
    CNS DRUGS, 2022, 36 (12) : 1285 - 1299
  • [8] Alemtuzumab reduces disease activity in treatment-naive patients with highly active relapsing-remitting multiple sclerosis
    Krieger, S.
    Lubetzki, C.
    Palmer, J.
    Margolin, D. H.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 106 - 107
  • [9] Markers of neuronal and glial damage in serum and cerebrospinal fluid of patients with Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome
    Boziki, Marina
    Chatziefstathiou, Athanasia
    Konstantinidou, Natalia
    Bakirtzis, Christos
    Kesidou, Evangelia
    Sintila, Stiliani-Angeliki
    Theotokis, Paschalis
    Canaslan, Sezgi
    Schmitz, Matthias
    Zerr, Inga
    Dafou, Dimitra
    Sklaviadis, Theodoros
    Grigoriadis, Nikolaos
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 895 - 896
  • [10] Glatiramer acetate in treatment-naive and immunomodulatory pre-treated relapsing-remitting multiple sclerosis patients
    Baumhackl, Ulf
    Pantev, Marina
    Klasser, Manfred
    MULTIPLE SCLEROSIS, 2008, 14 : S31 - S31